{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:39:05Z","timestamp":1787495945483,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1016\/s0959-8049(02)00487-2","type":"journal-article","created":{"date-parts":[[2002,12,30]],"date-time":"2002-12-30T14:08:58Z","timestamp":1041257338000},"page":"164-169","source":"Crossref","is-referenced-by-count":24,"title":["Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma"],"prefix":"10.1016","volume":"39","author":[{"given":"T","family":"B\u00e1nfalvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Gilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gergye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boldizs\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kremmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ott\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0959-8049(02)00487-2_BIB1","first-page":"705","article-title":"The histogenesis and biologic behaviour of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1997.15.3.1039","article-title":"Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of new staging system","volume":"15","author":"Buzaid","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB3","first-page":"721","article-title":"Determination of urinary 5-S-L-cysteinyl-L-dopa in serum by high performance liquid chromatography after prepurification with immobilised boric acid","volume":"7","author":"Kagedal","year":"1985","journal-title":"Pigment Cell"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB4","first-page":"218","volume":"5","author":"B\u00e1nfalvi","year":"1999","journal-title":"Serum levels of S-100B protein and 5-S-cysteinyldopa as markers of melanoma progression Pathol Oncol Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB5","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/0959-8049(95)00087-Y","article-title":"Clinical significance of serum S-100 in metastatic malignant melanoma","volume":"31A","author":"Guo","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB6","first-page":"601","article-title":"S-100 protein serum levels in cutaneous malignant melanoma","volume":"5","author":"Seregeni","year":"1998","journal-title":"Oncol. Rep"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB7","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.1997.232","article-title":"Elevated serum levels of S-100 and survival in metastatic malignant melanoma","volume":"75","author":"Buer","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/172460089400900408","article-title":"Correlation between lipid-associated sialic acid and tumour burden in melanoma","volume":"9","author":"Buzaid","year":"1994","journal-title":"Int J Biol Markers"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02306089","article-title":"Albertini, Rapaport Devaluation of new putative tumour markers for melanoma","volume":"3","author":"Miliotes","year":"1996","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB10","first-page":"5059","article-title":"Comparative study on the clinical use of protein S-100 B and MIA in melanoma patients","volume":"20","author":"Schmitz","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000219008","article-title":"The use of serological tumor markers for malignant melanoma","volume":"20","author":"Hauschild","year":"1997","journal-title":"Onkologie"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB12","first-page":"2203","article-title":"Schadendorf DComparison of S-100 protein and MIA protein as serum markers in malignant melanoma","volume":"20","author":"Djukanovic","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2001.19.3.824","article-title":"Serum S 100b protein as prognostic marker in malignant cuteneuos melanoma","volume":"19","author":"Martenson","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1046\/j.1365-2133.1998.02119.x","article-title":"Clinical prognostic relevance of serum S-100b protein in malignant melanoma","volume":"38","author":"Schoultz","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s004320050018","article-title":"Serum protein S-100b in patients with malignant melanoma detected by an immunoluminometric assay","volume":"126","author":"Wollina","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008390-199606000-00001","article-title":"Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells","volume":"6","author":"Benathan","year":"1996","journal-title":"Melanoma Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00008390-200008000-00008","article-title":"The value of cysteinyldopa in the follow up of disseminated malignant melanoma","volume":"10","author":"Karnell","year":"2000","journal-title":"Melanoma Res"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2340\/0001555577379381","article-title":"Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years experience of 50 patients","volume":"77","author":"Sasaki","year":"1998","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB19","first-page":"5073","article-title":"Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemoterapy","volume":"57","author":"Wimmer","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/1097-0142(19940201)73:3<629::AID-CNCR2820730321>3.0.CO;2-W","article-title":"Eguchi HEvaluation of melanin-related metabolites as markers of melanoma progression","volume":"73","author":"Horikoshi","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1046\/j.1365-2362.2000.00710.x","article-title":"Serum concentration of 5-S-cysteinyldopa in patients with melanoma","volume":"30","author":"B\u00e1nfalvi","year":"2000","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008390-199706000-00009","article-title":"Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma","volume":"7","author":"Hasegawa","year":"1997","journal-title":"Melanoma Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00008390-199702000-00009","article-title":"Serum levels of s-ICAM, and 5-S-cysteinyldopa as markers of melanoma progression","volume":"7","author":"Hirai","year":"1997","journal-title":"Melanoma Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/00015559850135797","article-title":"Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children","volume":"78","author":"Meyerhoffer","year":"1998","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-0749.1995.tb00653.x","article-title":"Seasonal variations in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxyl acid in healthy Japanese","volume":"8","author":"Wakamatsu","year":"1995","journal-title":"Pigment Cell Res."},{"key":"10.1016\/S0959-8049(02)00487-2_BIB26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2133.2000.03650.x","article-title":"Rising levels of serum S-100 protein precede other evidence of disease progression in patients with malignant melanoma","volume":"143","author":"Jury","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/S0959-8049(02)00487-2_BIB27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008390-200010000-00007","article-title":"Significance of serum protein S-100 levels in screening for metastasis: does protein S-100 enable early detection of melanoma recurrence?","volume":"10","author":"Shlagenhauff","year":"2000","journal-title":"Melanoma Res."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804902004872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804902004872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T12:00:33Z","timestamp":1704715233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804902004872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["S0959804902004872"],"URL":"https:\/\/doi.org\/10.1016\/s0959-8049(02)00487-2","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}